Amorcyte is a biopharm company engaged in the development of proprietary cellular therapies in cardiovascular disease, immunology and regenerative medicine primarily in the United States. Its lead product candidate, AMR-001, which is for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. For further information, visit the company’s Web site at www.neostem.com

EBD Group’s Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event.

Let us hear your thoughts below: